BioTime announced that updated results from a Phase I/IIa study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, will be presented at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting, to be held April 28 through May 2, 2019 at the Vancouver Convention Centre in Vancouver, BC, Canada. OpRegen is currently being evaluated in a Phase I/IIa clinical trial for the treatment of dry-age related macular degeneration.The abstract presentation, entitled, “Phase I/IIa Clinical Trial of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium Transplantation in Advanced Dry Form Age-Related Macular Degeneration: Interim Results,” will be presented as part of the Advances in Retinal Gene Therapy and Stem Cells Session on May 2, 2019 between 10:15 AM to 12:00 PM EDT in Session Number 530 by Eyal Banin, MD, PhD, Professor of Ophthalmology, Director, Center for Retinal and Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew University Medical Center. The abstract will provide updated data from patient cohorts 1 through 3 of the study and new data from the ongoing patient cohort 4 in better vision patients. In addition, BioTime will present preclinical results from its Vision Restoration Program, the Company’s proprietary program based on the ability to generate 3-dimensional human retinal tissue derived from pluripotent cells.
https://thefly.com/landingPageNews.php?id=2870235
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.